Enveric Biosciences, Inc.
ENVB
$5.90
$0.081.38%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 10.09% | -34.04% | 11.07% | 8.19% | 26.16% |
| Total Depreciation and Amortization | -52.36% | -52.83% | -5.15% | -2.37% | -11.48% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -84.25% | -41.23% | -42.05% | -36.66% | 243.66% |
| Change in Net Operating Assets | -142.74% | 126.48% | 14.01% | 326.29% | 188.14% |
| Cash from Operations | -123.82% | 34.58% | 7.96% | 25.10% | 66.17% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 477.91% | 596.28% | -10.75% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 89.04% | 99.99% |
| Cash from Financing | 478.02% | 1,205.52% | -33.18% | 349.01% | 593.05% |
| Foreign Exchange rate Adjustments | -151.89% | -376.92% | -148.15% | 45.41% | -39.54% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 332.23% | 49.37% | -49.52% | 55.99% | 86.11% |